High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1486-1492

  Seclén, Eduardo ^a   Garrido, Carolina ^a   González, María del Mar ^a   González Lahoz, Juan ^a   de Mendoza, Carmen ^a   Soriano, Vincent ^a   Poveda, Eva ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

CCR5 antagonists; Co receptor; Genotypic predictors; Tropism

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; VIRUS RNA; VIRUS DNA; VIRUS RECEPTOR;

ALGORITHM; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT TOOL; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GOLD STANDARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PHYLOGENY; PREDICTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; VIROGENESIS; VIRUS STRAIN; COMPARATIVE STUDY; DNA SEQUENCE; EVALUATION STUDY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; MONONUCLEAR CELL; PHYSIOLOGY; PLASMA; PROCEDURES; VIRAL TROPISM; VIROLOGY; VIRUS ATTACHMENT;

DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PLASMA; RECEPTORS, HIV; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VIRAL TROPISM; VIRUS ATTACHMENT;

EID: 77954180006     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq137     Document Type: Article

References (25)

1. Gulick RM, Su Z, Flexner C et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196: 304-12.
2. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
3. Door P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
4. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
5. Labernardiere J, Lebel-Binay S, Faudon JL et al. Tropism determination and performance of Phenoscript HIV-1 entry inhibitors assay. Antivir Ther 2004; 9: 141.
6. Hwang SS, Boyle TJ, Lyerly HK et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253:71-4.
7. Trouplin V, Salvatori F, Cappello F et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75: 251-9.
8. Roulet V, Rochas S, Labernardiere JL et al. HIV-1 PHENOSCRIPT ENV: a sensitive assay for the detection of HIV X4 minority species and determination of non-B subtype viral tropism. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections,Los Angeles, USA, 2007. Abstract 617. Alexandria, VA, USA: Foundation for Retrovirology and Human Health.http://www.retroconference.org/2007.
9. Cardozo T, Kimura T, Philpott S et al. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retrovir 2006; 23: 415-26.
10. Delobel P, Nugeyre MT, Cazabat M et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007; 45: 1572-80.
11. Jensen MA, Li FS, van't Wout AB et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-88.
12. Jensen MA, van't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5: 104-12.
13. Pillai S, Good B, Richman D et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19: 145-9.
14. Sing T, Low AJ, Beerenwinkel N et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12: 1097-106.
15. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-24.
16. Poveda E, Briz V, Roulet V et al. Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. AIDS 2007; 21: 1487-90.
17. Raymond S, Delobel P, Mavigner M et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: F11-6.
18. Poveda E, Seclén E, González MM et al. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63: 1006-10.
19. Chueca N, Garrido C, Alvarez M et al. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 2009; 81: 763-7.
20. Harrigan PR, McGovern R, Dong W et al. Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. Antivir Ther 2009; 14 Suppl 1: A17.
21. Obermeier M, Carganico A, Berg T et al. The Berlin Maraviroc cohort- influence of genotypic tropism testing results on therapeutic outcomes. Rev Antivir Ther 2009; 1:84-5.
22. Skrabal K, Low AJ, Dong W et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45: 279-84.
23. Garrido C, Roulet V, Chueca N et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008; 46: 887-91.
24. Verhofstede C, Vandekerckhove L, Eygen VV et al. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 2009; 50: 126-36.
25. Seclen E, Gonzalez MM, Soriano V et al. Dynamics of viral tropism in HIV infected patients under prolonged HIV-RNA suppression with HAART. Rev Antivir Ther 2009; 1: 55.